Effective treatment of non-fusion RET intragenic deletion lung adenocarcinoma with pralsetinib: a case report
RET fusions, the most common oncogenic RET alterations, occur in approximately 1–2% of non-small cell lung cancer (NSCLC) cases and represent well-established therapeutic targets. Pralsetinib, a selective RET kinase inhibitor, has demonstrated significant efficacy and tolerability in patients with R...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1546287/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|